Skip to content

Evaluation of Surgical Stress Index (SSI) During Sevoflurane/Remifentanil Anesthesia

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00791791
Enrollment
24
Registered
2008-11-17
Start date
2008-08-31
Completion date
2008-11-30
Last updated
2012-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Analgesia

Keywords

Anesthesia General, Anesthetics Inhalation, Stress measurement, Surgical Stress, Diagnostic Techniques and Procedures

Brief summary

The aim of the present prospective randomized study was to challenge the ability of SSI to detect painful stimulation during sevoflurane - remifentanil anesthesia.

Detailed description

General anesthesia can be considered as a combination of hypnosis, antinociception and immobility. Whereas monitoring of depth of hypnosis, and muscle relaxation can be regarded as accepted, determination of the nociception is based on clinical signs like somatic or autonomic responses. Recently, the multivariate surgical stress index (SSI)has been demonstrated to correlate with surgical stress intensity. Thus, SSI might be a useful variable to adjust analgesic drug administration in individual patients. We want to investigate whether SSI is able to indicate nociception following standardized noxious stimulation during balanced sevoflurane - remifentanil anesthesia.

Interventions

PROCEDUREstandardized pain stimulus

a tetanic stimulus (30s, 50 Hz, 60mA) applied as standardized pain stimulus

Sponsors

University Hospital Schleswig-Holstein
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Primary purpose
DIAGNOSTIC

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* age between 18 and 65 years * ASA physical status 1-2 * elective surgery in general anesthesia of 1 to 2 hours * written informed consent

Exclusion criteria

* pregnancy * history of cardiac arrhythmia * presence of any neuromuscular or neurological disease * use of CNS-active medication or abuse of alcohol or illicit drugs

Design outcomes

Primary

MeasureTime frame
SSI, compared to standard monitoring variablesduring anesthesia

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026